FIZE Medical raises $14 million to tackle critical patient care
FIZE Medical raises $14 million to tackle critical patient care
The company’s technology aims to improve hemodynamic status management, reducing mortality rates in intensive care units.
FIZE Medical, which develops fluid management systems for critically ill patients, has raised $14 million, led by Rapha Capital. The company, founded in 2011 by Noam Levine, currently employs about 40 people in Israel and the U.S. To date, the company has raised $29 million from investors, including Mendham Investment Group and Rapha Capital Management, led by Dr. Kevin Slawin – entrepreneur, surgeon, and urologist.
FIZE Medical has developed technology designed for intensive care that addresses the challenge of managing the hemodynamic status of critical patients. An inaccurate diagnosis can lead to serious complications and is a leading cause of death in intensive care units. In the U.S. alone, more than 4 million patients are hospitalized in intensive care units every year, with over a third of them experiencing circulatory shock, resulting in mortality rates of about 40%.
The round also saw participation from Valitas Ventures (part of the Tadmor Group), which specializes in go-to-market (GTM) strategies for health technologies, and eHealth Ventures, which focuses on investments in the health sector. As part of the collaboration, Tal Shnider, co-founder of Valitas and a former senior executive at Medtronic, will join the company’s board of directors as an observer. Additionally, Yair Hadar, a representative from eHealth Ventures, will also serve as an observer on the board.
Approximately 50% of intensive care patients develop acute kidney injury (AKI) during hospitalization, resulting in mortality rates of over 20%. Early detection of AKI can significantly reduce both morbidity and mortality.
FIZE Medical is now entering the commercialization phase after a successful launch last year in leading hospitals in the U.S. and Israel, where over 4,000 patients have already been monitored. The company will expand its operations in Japan and Europe in the coming year and, for this purpose, is expanding its production infrastructure in Israel and Vietnam. The company’s CEO, Dror Zerem, said: "Following our collaboration with Cicor in Vietnam to expand production capabilities and the expected receipt of CE certification in 2025 for operations in Europe, this new funding will allow us to accelerate our penetration into the U.S. healthcare market and facilitate a rapid entry into the European healthcare market."
